NCT07143968招募中2 期
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of Resmetirom for the Treatment of Metabolic Dysfunction- Associated Steatotic Liver Disease (MASLD) in People Living With Human Immunodeficiency Virus (HIV)
Naga P. Chalasani10 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2026年4月23日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 120
- 试验地点
- 10
- 主要终点
- Change from baseline in hepatic fat content at week 24
研究概览
简要总结
The purpose of this research study is to test the safety and effectiveness of the study drug, resmetirom, in participants with MASLD and HIV. This is a research study to test a drug that is already on the market with a population that was not included in the original clinical trials. Participants will be people over age 18 with HIV who are on antiretroviral therapy and have been diagnosed with MASLD.
Researchers will compare resmetirom to placebo (a look-alike substance that contains no drug) to see if resmetirom decreases the amount of fat in the liver.
Participants will:
- Complete 3 screening visits to determine eligibility.
- Take resmetirom or placebo every day for 24 weeks if eligible.
- Have 2 MRI scans to measure the amount of fat on the liver. One will be before treatment starts and one will be at the end of 24 weeks of treatment.
- Attend 3 scheduled clinic visits while on treatment for bloodwork and safety assessments.
- Participate in 3 phone calls while on treatment and one phone call 4 weeks after treatment is completed to check for safety and any health changes.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adults (≥18 years of age) with documented HIV.
- •Documented diagnosis of MASLD established by imaging (ultrasound, CT scan or MRI) or vibration-controlled transient elastography (VCTE) or liver biopsy within 12 months before screening.
- •Hepatic fat fraction ≥8% by MRI-PDFF.
- •Liver stiffness by VCTE ≥8 kPa and CAP≥263 dB/m
- •HIV-1 RNA <200 copies/mL for ≥6 months on antiretroviral therapy (ART) (must have screening HIV-1 RNA value and one clinical care value within 6 months prior to screening and up to the randomization that meet the criteria).
- •Stable ART regimen for ≥3 months prior to screening and stable up to the randomization and no active plans to change ART while on study.
- •Willingness to participate in the study.
排除标准
- •History of significant alcohol consumption (defined as >2 drinks/day on average for men, >1 drinks/day on average for women) for at least 3 consecutive months (12 consecutive weeks) within 5 year before screening
- •History of other acute or chronic liver disease, including, but not limited to autoimmune, primary biliary cholangitis, Wilson's disease, alpha 1 antitrypsin deficiency, hemochromatosis, hepatitis B virus (HBV), and ongoing or recent (within the past 3 years) hepatitis C RNA positivity.
- •History of liver transplant.
- •Liver biopsy or radiologic imaging consistent with the clinical presence of cirrhosis or portal hypertension at screening.
- •Participants whose Visit 2 ALT, AST, or alkaline phosphatase (ALP) values exceed their Visit 1 values by more than 50%.
- •Inability to undergo MRI testing
- •Uncontrolled T2DM defined as glycated hemoglobin (HbA1c) >9.5% at screening.
- •Any of the following laboratory values at screening:
- •ALT or AST >250 U/L.
- •Total bilirubin (TBL) >1.5 mg/dL and direct bilirubin > 0.5 mg/dL (unless due to Gilbert's disease or atazanavir use, per the opinion of the site investigator).
- •Platelet count <150,000/mm
- •Estimated glomerular filtration rate (e-GFR) <60 mL/min/1.73m2 using the chronic kidney disease-epidemiology collaboration (CKD-EPI) equation
- •International normalized ratio (INR) >1.
- •Albumin < 3.6 g/dL
- •Liver stiffness measurement (LSM) by VCTE > 20 kPa
- •Further exclusion criteria apply
研究组 & 干预措施
Treatment
Experimental
Resmetirom - 80mg or 100mg based on participant weight
干预措施: Resmetirom (Drug)
Placebo
Placebo Comparator
Placebo
干预措施: Placebo Control (Drug)
结局指标
主要结局
Change from baseline in hepatic fat content at week 24
时间窗: From baseline to the end of treatment at 24 weeks
次要结局
- Proportion of participants with reduction of at least 30% in hepatic fat content from baseline to week 24(Baseline to the end of treatment at week 24)
- Change from baseline in liver enzyme parameters, lipid profile and fasting glucose(From baseline to end of treatment at week 24)
研究者
Naga P. Chalasani
Professor of Medicine
Indiana University
研究点 (10)
Loading locations...
相似试验
已完成
3 期
A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis (RA)Rheumatoid ArthritisNCT02265705Eli Lilly and Company290
已完成
2 期
A Study to Evaluate the Efficacy and Safety of Therapeutic Hepatitis B VaccineHepatitis B, ChronicNCT04289987CHA Vaccine Institute Co., Ltd.134
已完成
2 期
Study Evaluating ERB-041 in Endometriosis in Reproductive-Age WomenEndometriosisNCT00110487Wyeth is now a wholly owned subsidiary of Pfizer200
已完成
2 期
A Study of LY2623091 in Participants With High Blood PressurePrimary HypertensionNCT02194465Eli Lilly and Company304
已完成
2 期
A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Persistent Asthma.AsthmaNCT00398645GlaxoSmithKline648